Direct-acting antiviral drugs can eradicate the hepatitis C virus, even in patients with advanced liver decompensation. But their outcomes may be better if treatment occurs after transplant, according to a recent study looking at this issue.
The goal of the study was to determine when life expectancy was improved with DAA treatment, before or after liver transplant. One reason these may differ is that the trade-off for improved liver function with early treatment is the risk for delay—or